Patents by Inventor Khalid Amanali MOHAMEDALI
Khalid Amanali MOHAMEDALI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230203467Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.Type: ApplicationFiled: November 3, 2022Publication date: June 29, 2023Applicant: Research Development FoundationInventors: Michael G. ROSENBLUM, Khalid Amanali MOHAMEDALI, Lawrence H. CHEUNG
-
Patent number: 11535838Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.Type: GrantFiled: June 15, 2020Date of Patent: December 27, 2022Assignee: Research Development FoundationInventors: Michael G. Rosenblum, Khalid Amanali Mohamedali, Lawrence H. Cheung
-
Patent number: 10920211Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.Type: GrantFiled: September 19, 2019Date of Patent: February 16, 2021Assignee: Research Development FoundationInventors: Michael G. Rosenblum, Khalid Amanali Mohamedali, Lawrence H. Cheung
-
Publication number: 20200308565Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.Type: ApplicationFiled: June 15, 2020Publication date: October 1, 2020Applicant: Research Development FoundationInventors: Michael G. ROSENBLUM, Khalid Amanali MOHAMEDALI, Lawrence H. CHEUNG
-
Patent number: 10738295Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.Type: GrantFiled: April 30, 2019Date of Patent: August 11, 2020Assignee: Research Development FoundationInventors: Michael G. Rosenblum, Khalid Amanali Mohamedali, Lawrence H. Cheung
-
Publication number: 20200010821Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.Type: ApplicationFiled: September 19, 2019Publication date: January 9, 2020Applicant: Research Development FoundationInventors: Michael G. ROSENBLUM, Khalid Amanali MOHAMEDALI, Lawrence H. CHEUNG
-
Publication number: 20190256837Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.Type: ApplicationFiled: April 30, 2019Publication date: August 22, 2019Applicant: Research Development FoundationInventors: Michael G. ROSENBLUM, Khalid Amanali MOHAMEDALI, Lawrence H. CHEUNG
-
Patent number: 10323239Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.Type: GrantFiled: March 9, 2018Date of Patent: June 18, 2019Assignee: Research Development FoundationInventors: Michael G. Rosenblum, Khalid Amanali Mohamedali, Lawrence H. Cheung
-
Publication number: 20180201918Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.Type: ApplicationFiled: March 9, 2018Publication date: July 19, 2018Applicant: Research Development FoundationInventors: Michael G. ROSENBLUM, Khalid Amanali MOHAMEDALI, Lawrence H. CHEUNG
-
Patent number: 9951325Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.Type: GrantFiled: July 2, 2014Date of Patent: April 24, 2018Assignee: Research Development FoundationInventors: Michael G. Rosenblum, Khalid Amanali Mohamedali, Lawrence H. Cheung
-
Patent number: 9499807Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.Type: GrantFiled: July 2, 2014Date of Patent: November 22, 2016Assignee: Research Development FoundationInventors: Michael G. Rosenblum, Khalid Amanali Mohamedali, Lawrence H. Cheung
-
Patent number: 9096840Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.Type: GrantFiled: October 4, 2013Date of Patent: August 4, 2015Assignee: Research Development FoundationInventors: Michael G. Rosenblum, Khalid Amanali Mohamedali, Lawrence H. Cheung
-
Publication number: 20150010556Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.Type: ApplicationFiled: July 2, 2014Publication date: January 8, 2015Applicant: RESEARCH DEVELOPMENT FOUNDATIONInventors: Michael G. ROSENBLUM, Khalid Amanali MOHAMEDALI, Lawrence H. CHEUNG
-
Publication number: 20140314760Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.Type: ApplicationFiled: July 2, 2014Publication date: October 23, 2014Applicant: RESEARCH DEVELOPMENT FOUNDATIONInventors: Michael G. ROSENBLUM, Khalid Amanali MOHAMEDALI, Lawrence H. CHEUNG
-
Publication number: 20140140976Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.Type: ApplicationFiled: October 4, 2013Publication date: May 22, 2014Applicant: RESEARCH DEVELOPMENT FOUNDATIONInventors: Michael G. ROSENBLUM, Khalid Amanali MOHAMEDALI, Lawrence H. CHEUNG